ArticleDiabetology & metabolic syndrome2026
Association of serum vitamin C and E levels with mortality in individuals with metabolic syndrome.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExisting evidence suggests the importance of oxidative stress in the etiology of metabolic syndrome (MetS), which is a growing global health problem. However, the impact of serum antioxidant vitamins (C and E) levels on the clinical outcomes of the MetS population is unknown.
methodsThis cohort study included 2102 adults diagnosed with MetS, who participated in the National Health and Nutrition Examination Survey from 2003 to 2006. Serum levels of vitamin C, α-tocopherol, and γ-tocopherol were measured. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated using Cox proportional hazards models to analyze the association between serum levels of vitamins and the risk of mortality from all causes, CVD, and cancer. Analyses controlled for demographic characteristics, body mass index, smoking, drinking, diabetes, hypertension, and dyslipidemia.
resultsAmong the 2102 participants, 731all-cause deaths were documented, including 270 CVD deaths and 52 cancer deaths. Compared to the reference group with serum vitamin C levels of 0.02-0.65 mg/dL, the multivariable-adjusted HRs for high vitamin C levels (1.08-4.26 mg/dL) were 0.65 (95% CI, 0.53-0.79) for all-cause mortality and 0.60 (95% CI, 0.42-0.85) for CVD mortality. Compared to the reference group with serum α-tocopherol levels of 354-1139 µg/dL, the adjusted HRs were 0.52 (95% CI, 0.33-0.83) for mid-range α-tocopherol levels (1140-1590 µg/dL) and 0.76 (95% CI, 0.46-1.25) for high-range levels (1591-6405 µg/dL) for cancer mortality. For serum γ-tocopherol, compared to the reference group (16-190 µg/dL), the HR for mid-range levels (191-315 µg/dL) was 1.79 (95% CI, 1.25-2.55) and for high-range levels (316-3122 µg/dL) was 1.74 (95% CI, 1.10-2.75) for CVD mortality.
conclusionsOur study highlights the clinical value of antioxidant vitamins in predicting the survival of the MetS population. Vitamin C are associated with a reduced risk of death from all causes and CVD in individuals with MetS. Mid-range α-tocopherol levels may decrease the risk of cancer mortality, while high-range γ-tocopherol levels could increase the risk of CVD mortality. Individuals with MetS may require more careful antioxidant vitamins supplement to prevent the development of other diseases and thereby reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.